Current antineoplastic treatments are not sufficient to cure cancer, in part due to lack efficacy and/or selectivity. Further, they often display significant side effects calling for new therapeutic approaches.
The invention consists in the design, realization and administration of peptides that target hexokinase 2 (HK2) specifically in tumors and display antineoplastic activity.
HK2 is glycolytic enzyme that contributes to metabolism, growth and death inhibition of tumor cells. Its expression is associated with poor prognosis and chemotherapeutic/radiation resistance in diverse solid and hematopoietic tumors.